Vimarsana
Biggest News Aggregation in the World

Page 5 - World Dynamix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from World Dynamix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In World Dynamix Today - Breaking & Trending Today

Primary Care Providers Report a High Unmet Need for New Therapeutic Treatment Options for Chronic Kidney Disease, Despite Earlier Intervention and Referrals to Nephrologists, Spherix Reports - Vimarsana News

Primary Care Providers Report a High Unmet Need for New Therapeutic Treatment Options for Chronic Kidney Disease, Despite Earlier Intervention and Referrals to Nephrologists, Spherix Reports

/PRNewswire/ -- Approximately 37 million Americans have chronic kidney disease (CKD)—that is one out of every seven U.S. adults.1 Many of these patients are...

New Research from Spherix Finds Increased Use of SGLT2 Inhibitors Across the EU5, Including AstraZeneca's Forxiga (Farxiga in US), in the Management of IgA Nephropathy Patients - Vimarsana News

New Research from Spherix Finds Increased Use of SGLT2 Inhibitors Across the EU5, Including AstraZeneca's Forxiga (Farxiga in US), in the Management of IgA Nephropathy Patients

/PRNewswire/ -- Glomerulonephritis is a major contributor of end-stage renal disease across the globe, with IgA nephropathy (IgAN), also known as Berger's...

European Nephrologists Lead the Way with Adoption of Astellas/FibroGen's HIF-PH inhibitor, EVRENZO (roxadustat), for Anemia of CKD Treatment in Both Dialysis and Non-Dialysis Settings, Spherix Report Finds - Vimarsana News

European Nephrologists Lead the Way with Adoption of Astellas/FibroGen's HIF-PH inhibitor, EVRENZO (roxadustat), for Anemia of CKD Treatment in Both Dialysis and Non-Dialysis Settings, Spherix Report Finds

/PRNewswire/ -- The European regulatory authorities tend to be moving in a different direction than U.S. Food and Drug Administration (FDA) regarding novel...

Novartis' Cosentyx and Eli Lilly's Taltz Remain Leaders in US and EU5 Psoriatic Arthritis Switching Market, but Janssen's Tremfya and AbbVie's Skyrizi Are Picking Up Steam, Spherix Reports - Vimarsana News

Novartis' Cosentyx and Eli Lilly's Taltz Remain Leaders in US and EU5 Psoriatic Arthritis Switching Market, but Janssen's Tremfya and AbbVie's Skyrizi Are Picking Up Steam, Spherix Reports

/PRNewswire/ -- Spherix Global Insights, a leading market intelligence firm specializing in immunology-based research and insights, recently published several...

Spherix Global Insights Announces Entry into Asia-Pacific Research with Upcoming IgA Nephropathy Market and Pipeline Assessment in Japan - Vimarsana News

Spherix Global Insights Announces Entry into Asia-Pacific Research with Upcoming IgA Nephropathy Market and Pipeline Assessment in Japan

/PRNewswire/ -- Glomerulonephritis is a major contributor of end-stage renal disease across the globe, with IgA nephropathy (IgAN), also known as Berger's...